Zobrazeno 1 - 10 of 14 pro vyhledávání: '"Erin O'Boyle"'
1
Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy
Autor: Erin O'Boyle, Ralph V. Boccia, William Cooper
Publikováno v: The Journal of Community and Supportive Oncology. 13:38-46
BACKGROUND A phase 3 trial in patients with cancer who received chemotherapy has shown that subcutaneous (SC) APF530, a sustained-delivery formulation of granisetron, is noninferior to palonosetron in preventing acute (0-24 hours) and delayed (>24-12
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe0c3d07fd2d6f055ba62e1415a7f096
https://doi.org/10.12788/jcso.0107
Zobrazit plný text záznamu
3
Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria
Autor: Harry Raftopoulos, Richard J. Gralla, Erin O'Boyle, William Cooper, Ralph V. Boccia
Publikováno v: Future oncology (London, England). 11(18)
Background: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, APF530 500 mg was noninferior to palonosetron 0.25 mg in preventing acute chemotherapy-induced nausea and vomiting (CINV) after moderately (MEC) or high
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60724a100cc1ab0dd9e0d4d5f31f9df4
https://pubmed.ncbi.nlm.nih.gov/26289588
Zobrazit plný text záznamu
4
A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation
Autor: Albert J Dietz, Erin O'Boyle, Thomas E. Moon, Jay W. Mason
Publikováno v: Cancer Management and Research
Jay W Mason,1 Thomas E Moon,2 Erin O’Boyle,3 Albert Dietz41Department of Medicine, University of Utah, Salt Lake City, UT, 2Tarizona eHealth Services, Inc., San Carlos, CA, 3AP Pharma, Redwood City, CA, 4Spaulding Clinical Research, West Bend, WI,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1ed85ed03740f6977d6dce256fddc8b
https://www.dovepress.com/a-randomized-placebo-controlled-four-period-crossover-definitive-qt-st-peer-reviewed-article-CMAR
Zobrazit plný text záznamu
5
Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials
Autor: Carrie Smith, Ronald Yanagihara, Marek Spaczyński, William Cooper, Erin O’Boyle, Ralph Boccia, Nash Gabrail
Publikováno v: Cancer Management and Research
Nashat Gabrail,1 Ronald Yanagihara,2 Marek Spaczyński,3 William Cooper,4 Erin O'Boyle,5 Carrie Smith,1 Ralph Boccia6 1Gabrail Cancer Center, Canton, OH, USA; 2St Louise Regional Hospital, Gilroy, CA, USA; 3Department of Gynecology, Obstetrics and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5860428d67eed8bf8efcb51cb7ab842
https://doi.org/10.2147/cmar.s72626
Zobrazit plný text záznamu
6
Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron
Autor: Erin O’Boyle, Mark S Gelder, Thomas Ottoboni
Publikováno v: Journal of Experimental Pharmacology
Thomas Ottoboni,1 Mark S Gelder,1 Erin O’Boyle2 1Heron Therapeutics, Inc., Redwood City, CA, USA; 2FibroGen, Inc., San Francisco, CA, USA Abstract: Granisetron and other 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are first-line agents
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::971e7e267647027d2c234d446175c537
https://doi.org/10.2147/jep.s68880
Zobrazit plný text záznamu
8
Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy
Autor: William Cooper, Erin O'Boyle, Ralph V. Boccia
Publikováno v: Journal of Clinical Oncology. 32:9645-9645
9645 Background: APF530 provides controlled, sustained release of granisetron for preventing acute (0-24 h) and delayed (24-120 h) CINV. In a phase 3 trial measuring complete response (CR; no emesi...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::88bd363cad653ce691a2c18e54b5c0bb
https://doi.org/10.1200/jco.2014.32.15_suppl.9645
Zobrazit plný text záznamu
9
Sustainability of antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of moderately (MEC) and highly (HEC) emetogenic chemotherapy regimens: Results of a randomized phase III trial
Autor: Erin O'Boyle, William Cooper, Ralph V. Boccia
Publikováno v: Journal of Clinical Oncology. 31:9626-9626
9626 Background: Patients receiving MEC or HEC were administered subcutaneous (SC) APF530 500 mg, a sustained delivery formulation of granisetron (10 mg). The complete antiemetic response rates (CR; no emetic episodes and no rescue medication) were n
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51904ed3d31a2b321f9a5edd5d7e3a36
https://doi.org/10.1200/jco.2013.31.15_suppl.9626
Zobrazit plný text záznamu
10
Comparison of the effects of subcutaneous APF530, intravenous granisetron, moxifloxacin, and placebo on the QT interval in humans
Autor: Jay W. Mason, Albert J Dietz, Thomas E. Moon, Erin O'Boyle
Publikováno v: Journal of Clinical Oncology. 31:e20539-e20539
e20539 Background: This study evaluated effects of subcutaneous (SC) APF530 (sustained-release granisetron) and intravenous (IV) granisetron on placebo-adjusted change from baseline in QT corrected with the Fridericia method (QTcF) over 48 h (ddQTcF)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c4eae2e50ebacd5c6366fcfc0d28aa6a
https://doi.org/10.1200/jco.2013.31.15_suppl.e20539
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje